← Back to Search

Procedure

MRI-Guided Surgery for Glioblastoma

N/A
Waitlist Available
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Newly diagnosed glioblastoma
Be older than 18 years old
Must not have
Unable to be medically cleared for surgery for resective treatment of glioblastoma
Previous molecular, immuno, chemotherapy or radiation therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months, 6 months, 12 months, 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether removing tumor cells found in non-enhancing regions of the brain can improve survival in glioblastoma patients.

Who is the study for?
This trial is for individuals with newly diagnosed glioblastoma, a type of brain cancer. Participants must be eligible for standard care and FDA approved therapies. The study aims to include those who can potentially benefit from an advanced MRI technique during surgery.
What is being tested?
The trial tests whether using a pH-sensitive MRI method called CEST during surgery to remove glioblastoma improves survival rates. Patients are randomly chosen to either have this new technique or the standard treatment, comparing their progression-free and overall survival.
What are the potential side effects?
Since the intervention involves surgical procedures guided by advanced imaging, potential side effects may include typical risks associated with brain surgery such as infection, bleeding, neurological deficits, and reactions to contrast agents used in MRI.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been recently diagnosed with glioblastoma.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot undergo surgery for my glioblastoma.
Select...
I have had cancer treatment like chemo, radiation, or targeted therapy before.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months, 6 months, 12 months, 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months, 6 months, 12 months, 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression free survival
Secondary study objectives
Overall survival
Quality of life metrics via karnofsky performance scale

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CEST ResectionExperimental Treatment1 Intervention
CEST MRI Based Resection of glioblastoma with standard of care adjuvant therpay (temozolomide + radiation therapy)
Group II: Standard of CareActive Control1 Intervention
Standard of care glioblastoma resection with standard of care adjuvant therapy (temozolomide + radiation therapy)

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,567 Previous Clinical Trials
10,266,940 Total Patients Enrolled
~40 spots leftby Jan 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top